Publications - Corcept Therapeutics

PUBLICATIONS

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.

“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.

Nanda R. • 2011 • Semin Oncol. 2011;38(2):254-62.

Minireview: nuclear receptors and breast cancer.

Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.

The biology of hormone refractory prostate cancer. Why does it develop?

Isaacs JT • 1999 • Urol Clin North Am. 1999;26(2):263-73.

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.

Isikbay et al. • 2014 • Horm Cancer. 2014;5(2):72-89.

Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.

Skor et al. • 2013 • Clin Cancer Res. 2013;19(22):6163-72.

Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.

Stringer-Reasor et al. • 2015 • Gynecol Oncol. 2015;138(3):656-62.

Differential targeting of brain stress circuits with a selective glucocorticoid receptor modulator.

Zalachoras et al. • 2013 • Proc Natl Acad Sci U S A. 2013;110(19):7910-7915.

A randomized phase I trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel, Abraxane®) with or without mifepristone for advanced breast cancer

Nanda et al. • 2013 • Cancer Res 2013;73(24 Suppl): Abstract nr P2-16-21.

Administration of a selective glucocorticoid antagonist attenuates electroconvulsive shock-induced retrograde amnesia.

Andrade et al. • 2012 • J Neural Transm (Vienna). 2012;119(3):337-44.

Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer.

Baker et al. • 2015 • Cancer Manag Res. 2015;7:361-8.